PMOS (Formerly PCOS): Why Testosterone, Menstrual Patterns, Glucose Testing, and Metabolic Risk Must Be Read Together

Polyendocrine Metabolic Ovarian Syndrome (PMOS) is the new name for the condition historically known as Polycystic Ovary Syndrome (PCOS). The name change reflects a central clinical reality: PMOS is not simply an ovarian condition and it is not defined by ovarian “cysts.” It is a long-term reproductive, endocrine, ovarian, and metabolic pattern that can affect menstrual cycles, ovulation, androgen levels, fertility, glucose regulation, cholesterol, blood pressure, skin, hair, sleep, liver health, and emotional well-being.

The Endocrine Society announced the PMOS name change in May 2026 following a global consensus process involving patients, clinicians, researchers, and more than 50 professional and patient organizations. The transition from PCOS to PMOS is expected to continue through the 2028 international guideline update, so both names remain important for patient education and search.

Laboratory testing can provide objective information about androgen excess, ovulation, conditions that can mimic PMOS, and metabolic risks that may not cause obvious symptoms. However, there is no single PMOS blood test, and laboratory testing alone cannot confirm or exclude the condition. Results need to be interpreted with menstrual history, symptoms, medications, pregnancy status, fertility goals, physical findings, and—when needed—ultrasound or anti-Müllerian hormone (AMH).

Ulta Lab Tests provides direct access to many relevant laboratory tests where available. Testing can help patients establish a baseline and prepare for a more informed conversation with a qualified healthcare professional. Lab testing is informational and does not replace professional medical advice, diagnosis, imaging, or treatment.

Key Takeaways

• PMOS is the 2026 name for PCOS. It describes a whole-body endocrine, metabolic, ovarian, and reproductive pattern rather than an ovarian-cyst disorder.
• Adults generally meet the diagnostic framework when two of three features are present after other causes are excluded: hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology.
• Total and free testosterone are the primary biochemical androgen tests. High-quality methods such as LC-MS/MS are preferred for total testosterone.
• AMH should not be used alone. If irregular cycles and hyperandrogenism already establish two diagnostic features, AMH or ultrasound may not be needed simply to document a third.
• Glucose and cardiovascular risk matter at any body size. The 75-g oral glucose tolerance test (OGTT) has a special role because fasting glucose or A1C can miss impaired glucose tolerance.
• Fasting insulin and the LH-to-FSH ratio are not stand-alone PMOS tests.
• Long-term monitoring should follow meaningful outcomes such as glucose, lipids, liver markers, iron status, thyroid abnormalities, blood pressure, symptoms, and fertility goals rather than repeatedly chasing testosterone or AMH values.

What Is PMOS, Formerly PCOS?

PMOS is a heterogeneous hormonal and metabolic syndrome that can affect ovarian function, menstrual cycles, androgen production, fertility, glucose metabolism, cardiovascular risk, sleep, and psychological health. The condition can look different from one person to another and can change across the lifespan.

One person may first notice unpredictable periods and acne. Another may have excess facial or body hair. Another may seek help for infertility. Someone else may first discover the metabolic side of PMOS after an abnormal glucose tolerance test, high triglycerides, or elevated liver enzymes.

The former name “polycystic ovary syndrome” caused understandable confusion. The follicles seen with polycystic ovarian morphology are not the same as typical pathological ovarian cysts. A person does not need ovarian cysts—and may not even need ovarian morphology—to meet PMOS diagnostic criteria.

Quick answer: PMOS is not diagnosed from one hormone value or by finding ovarian “cysts.” Diagnosis depends on a connected pattern of ovulatory function, androgen-related findings, ovarian morphology when needed, and exclusion of other causes.

How Is PMOS Diagnosed in Adults?

Current international guidance generally supports an adult diagnosis when at least two of the following three features are present after other plausible causes have been excluded:

1. Clinical or biochemical hyperandrogenism—for example, hirsutism or elevated total or free testosterone.
2. Ovulatory dysfunction—commonly reflected by irregular, infrequent, or absent menstrual cycles.
3. Polycystic ovarian morphology—defined by ultrasound or, in appropriate adults, AMH used within the diagnostic algorithm.

A person does not need all three features. When irregular cycles and clinical or biochemical hyperandrogenism are already present, ultrasound or AMH is generally not required simply to create a third abnormal finding.

Menstrual Patterns Are a Diagnostic Test of Their Own

Menstrual history is not just background information. It can provide direct evidence about ovulatory function. For adults more than three years after menarche through the perimenopausal years, irregular cycles generally include:

• cycles shorter than 21 days,
• cycles longer than 35 days,
• fewer than eight cycles per year, or
• a cycle lasting more than 90 days once more than one year has passed since menarche.

These thresholds are diagnostic clues, not a stand-alone diagnosis. Pregnancy, thyroid disease, hyperprolactinemia, hypothalamic dysfunction, ovarian insufficiency, medications, and other conditions can also disrupt menstruation.

Apparently regular bleeding does not always prove that ovulation occurred. When confirming ovulation would change the evaluation or fertility plan, a properly timed Progesterone Test may help determine whether ovulation occurred.

Is PMOS evaluated differently in adolescents?

Yes. Acne, irregular cycles, and multifollicular ovaries can be normal features of puberty. In adolescents, both persistent ovulatory dysfunction and clinical or biochemical hyperandrogenism are generally required. Ultrasound and AMH are not recommended for adolescent diagnosis because specificity is poor. Someone with suggestive features who does not yet meet criteria may be followed over time rather than labeled prematurely.

Testosterone Testing in PMOS: Method and Context Matter

Total Testosterone and Free Testosterone are the preferred biochemical tests when androgen excess needs laboratory confirmation. Sex Hormone-Binding Globulin (SHBG) helps place testosterone into context and can be used in calculations such as the free androgen index.

Why LC-MS/MS matters

Testosterone concentrations in women are relatively low, so assay quality matters. The international guideline recommends validated, highly accurate tandem mass spectrometry methods such as LC-MS/MS for total testosterone rather than less accurate direct immunoassays when evaluating biochemical hyperandrogenism.

If total and free testosterone are not elevated but clinical suspicion remains, DHEA-S or Androstenedione may add information, although both are less specific.

Hormonal contraception can change androgen results

Combined oral contraceptives can increase SHBG and suppress gonadotropin-dependent androgen production, making biochemical androgen assessment difficult to interpret. Do not stop hormonal contraception or another prescribed medication simply to obtain a different result. If androgen testing is essential, medication decisions should be made with the prescribing clinician.

Very high androgen levels, rapidly progressive hirsutism, virilization, voice deepening, clitoral enlargement, or abrupt muscle changes are not typical routine PMOS findings and warrant prompt professional evaluation for other causes.

AMH vs. Ultrasound: When Is Ovarian Morphology Actually Needed?

Anti-Müllerian Hormone (AMH) and ovarian ultrasound should answer a specific diagnostic question, not simply be added to every PMOS workup.

1. AMH should not be used alone to diagnose PMOS.
2. If an adult already has ovulatory dysfunction plus clinical or biochemical hyperandrogenism, AMH or ultrasound is generally unnecessary simply to document a third criterion.
3. AMH and ultrasound should not routinely be ordered together solely to increase the chance of finding polycystic ovarian morphology.

AMH is not recommended for adolescent PMOS diagnosis. Age, body composition, hormonal contraception, ovarian surgery, cycle timing, assay method, and population-specific cutoffs can also affect interpretation.

Why PMOS Matters for Whole-Body Health

PMOS may first present as a menstrual, skin, or fertility concern, but its effects can extend well beyond reproductive health.

Reproductive and hormonal health

PMOS may be associated with irregular or absent periods, inconsistent ovulation, infertility, elevated androgens, hirsutism, persistent acne, and scalp hair thinning. Clinical hirsutism can be meaningful even when testosterone is within the laboratory reference interval.

Glucose and metabolic health

Insulin resistance is an important biological feature of PMOS. People with PMOS have an increased risk of impaired fasting glucose, impaired glucose tolerance, and type 2 diabetes regardless of BMI. Glycemic status should therefore be assessed when PMOS is identified and reassessed according to individual risk.

For a deeper explanation of why a normal A1C may not reveal the full glucose picture, see PMOS (Formerly PCOS) and Diabetes Risk: Why a Normal A1C May Not Tell the Whole Story.

Cholesterol and cardiovascular risk

PMOS may be associated with high triglycerides, low HDL cholesterol, elevated LDL cholesterol, high blood pressure, impaired glucose tolerance, and other cardiometabolic risk factors. A Lipid Panel is recommended at diagnosis regardless of age or BMI. Blood pressure should also be measured at least annually and when planning pregnancy or seeking fertility treatment.

For broader cardiometabolic context, see Ulta Lab Tests’ Diabetes and Prediabetes Blood Tests and Metabolic Health Blood Tests pillar guides.

Liver, sleep, endometrial, and emotional health

Metabolic dysfunction can coexist with abnormal liver enzymes or metabolic dysfunction-associated steatotic liver disease. PMOS is also associated with a higher prevalence of obstructive sleep apnea independent of BMI; blood tests do not diagnose sleep apnea, so symptoms such as loud snoring, unrefreshing sleep, and daytime sleepiness require an appropriate sleep evaluation.

Long intervals without ovulation can expose the endometrium to prolonged estrogen stimulation without regular progesterone exposure. PMOS is associated with increased endometrial-hyperplasia risk, although the absolute risk of endometrial cancer remains low and routine cancer screening is not recommended solely because PMOS is present. Prolonged amenorrhea or unusual bleeding should be discussed with a clinician.

Depression, anxiety, eating disorders, body-image concerns, and reduced quality of life can also occur. These concerns cannot be explained or managed by a testosterone or glucose result alone.

Common Symptoms, Risk Factors, and Warning Signs

Symptom or finding	What it may suggest	Laboratory information that may help
Irregular, infrequent, or absent periods	Ovulatory dysfunction, pregnancy, thyroid dysfunction, hyperprolactinemia, medication effects, or another endocrine cause	hCG, TSH, Free T4 when indicated, Prolactin, Total Testosterone, SHBG, 17-Hydroxyprogesterone
Excess facial/body hair, acne, or scalp hair thinning	Clinical androgen excess; PMOS is common, but adrenal, medication-related, and rare tumor causes must be considered	Total Testosterone, Free Testosterone, SHBG, DHEA-S, Androstenedione
Difficulty conceiving	Inconsistent ovulation or another fertility factor	Progesterone, TSH, Prolactin, pregnancy testing, and clinician-directed fertility evaluation
Acanthosis nigricans, increased waist size, family history of diabetes, or prior gestational diabetes	Higher likelihood of impaired glucose tolerance or diabetes	75-g OGTT, Fasting Glucose, A1C, Lipid Panel
Fatigue, poor exercise tolerance, or hair shedding	Glucose dysregulation, thyroid disease, anemia, iron deficiency, sleep apnea, nutrient deficiency, or another condition	CBC, Ferritin, Iron and TIBC, TSH, Vitamin B12, glucose testing
Heavy or prolonged bleeding	Anovulatory bleeding, pregnancy-related complication, structural uterine disease, or anemia	Pregnancy testing, CBC, Ferritin; clinical evaluation may be needed
Rapid virilization, voice deepening, clitoral enlargement, or rapidly increasing muscle mass	Possible androgen-producing disorder or another non-PMOS cause	Prompt clinician-directed Total Testosterone, DHEA-S, and further evaluation

When to seek prompt medical care

Seek prompt or urgent medical evaluation for severe pelvic or abdominal pain, fainting, very heavy bleeding, a positive pregnancy test with pain or bleeding, severe hyperglycemia symptoms, sudden neurological symptoms, rapid virilization, or other abrupt and concerning changes. Direct-access laboratory testing should not delay urgent care.

The Role of Lab Testing in PMOS

Lab testing is most useful when each test is chosen to answer a defined clinical question:

1. Is biochemical androgen excess present?
2. Is ovulation occurring when that information matters?
3. Could another endocrine condition explain the menstrual or androgen pattern?
4. Is glucose regulation or cholesterol already abnormal?
5. Could fatigue, hair loss, bleeding, or poor recovery have another explanation?

For broader context on what laboratory tests can and cannot establish, see The Complete Guide to Lab Tests and Blood Work.

Why patterns matter more than one result

A mildly elevated testosterone result means something different depending on SHBG, symptoms, medication use, assay method, menstrual history, and the presence of other abnormalities. Likewise, normal fasting glucose does not necessarily exclude impaired glucose tolerance, and a low progesterone value can reflect mistimed collection rather than true anovulation.

Related PMOS Lab Tests and Biomarkers

Androgen, ovulation, and diagnostic-exclusion tests

Test	What it measures / why it matters	Important limitations
Testosterone, Total, MS	Primary biochemical marker for androgen excess; LC-MS/MS is preferred for concentrations typical in women.	A normal result does not exclude clinical hirsutism or PMOS. Method and medication context matter.
Free Testosterone and SHBG	Add information about biologically available testosterone and binding-protein effects.	Results depend on method; hormonal contraception, thyroid status, liver function, body composition, and estrogen exposure can affect SHBG.
Testosterone Total and Free with SHBG	Convenient combined assessment when biochemical hyperandrogenism is being evaluated.	Still requires clinical context and does not diagnose PMOS alone.
DHEA-S	Predominantly adrenal androgen; may be useful when testosterone is not elevated or an adrenal contribution is considered.	Less specific for PMOS; marked elevation or rapid virilization requires broader evaluation.
Androstenedione	Ovarian and adrenal androgen that may add information when testosterone does not explain symptoms.	Less specific than testosterone and should not be used alone.
Progesterone	Can provide evidence that ovulation occurred when appropriately timed.	A low value can reflect anovulation or simply incorrect timing; a universal “day 21” rule does not fit every cycle.
hCG Total Quantitative	Helps assess pregnancy when periods are late or absent.	Very early testing can be negative; one value cannot determine pregnancy location or viability.
TSH and Free T4	Evaluate thyroid dysfunction as a potential cause of menstrual, fertility, weight, or fatigue symptoms.	Interpret with symptoms, medications, pregnancy status, and clinical context.
Prolactin	Persistent elevation can interfere with ovulation and menstruation.	Mild elevations may reflect stress, sleep, exercise, food intake, breast stimulation, medications, or macroprolactin and may need confirmation.
17-Hydroxyprogesterone	Screens for nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.	Elevated screening values do not establish the diagnosis and may require follow-up testing.
FSH, LH, and Estradiol	Selected ovarian-pituitary context when the differential includes ovarian insufficiency, hypothalamic dysfunction, amenorrhea, or fertility questions.	Not required for every PMOS evaluation. The LH-to-FSH ratio is not a validated stand-alone PMOS diagnostic test.
AMH	Can help define polycystic ovarian morphology in appropriate adults within the diagnostic algorithm.	Not a stand-alone test; not recommended for adolescents; may be unnecessary when irregular cycles and hyperandrogenism are already present.
Cortisol, Total when clinically indicated	May be part of a clinician-directed evaluation when findings raise concern for Cushing syndrome.	Cortisol is not routine PMOS screening and should not be added to every PMOS panel.

Glucose, cardiovascular, and metabolic tests

Test	Why it may matter in PMOS	Important limitations
Glucose Tolerance Test, 2 Specimens, 75g	The guideline-preferred glycemic assessment in PMOS; can reveal impaired glucose tolerance that fasting glucose or A1C may miss.	Requires fasting, a measured glucose drink, and timed collection.
Glucose	Provides a point-in-time fasting glucose value.	May remain normal despite abnormal post-challenge glucose handling.
Hemoglobin A1C	Reflects average glycemia over roughly two to three months and may be used when an OGTT cannot be completed.	Less accurate than OGTT for PMOS glycemic assessment and can be influenced by anemia, altered red-cell turnover, kidney disease, pregnancy, and hemoglobin variants.
Lipid Panel	Assesses total cholesterol, LDL, HDL, and triglycerides; recommended at diagnosis regardless of age or BMI.	Does not diagnose PMOS; follow-up depends on the initial pattern and overall cardiovascular risk.
Comprehensive Metabolic Panel (CMP)	Provides glucose, electrolytes, kidney markers, liver enzymes, bilirubin, albumin, and proteins for broader metabolic context.	Normal liver enzymes do not exclude metabolic liver disease.
Apolipoprotein B (ApoB) when appropriate	May add cardiovascular-risk information when triglycerides are high or metabolic risk is otherwise elevated.	Not a routine PMOS diagnostic test.

Tests for connected symptoms and separate clinical questions

Test	When it may add value	Important limitation
CBC with Differential and Platelets	Heavy bleeding, fatigue, reduced exercise tolerance, or suspected anemia.	Does not identify the cause of bleeding or diagnose PMOS.
Ferritin and Iron and TIBC	Hair shedding, fatigue, heavy bleeding, or suspected iron depletion.	Ferritin can rise with inflammation; interpretation may require the full iron pattern.
Vitamin B12 and Folate, Serum	Selected nutritional, anemia, neurologic, restrictive-diet, or medication-related questions.	Not routine PMOS diagnostic tests.
Vitamin D, 25-Hydroxy Total	May be appropriate when there is an independent vitamin-D indication or deficiency risk.	Does not diagnose PMOS and should not be automatically added to every PMOS panel.

A Practical Seven-Step PMOS Testing Pathway

Not everyone needs every test. The most useful approach is question-driven and should reflect symptoms, menstrual history, medications, reproductive goals, previous results, and healthcare-provider recommendations.

1. Document the menstrual and symptom pattern

Record cycle length, number of cycles per year, any cycle longer than 90 days, acne or hair changes, scalp hair loss, weight and waist trends, pregnancy possibility, fertility goals, current or recent hormonal contraception, medications, supplements, and family history of PMOS or type 2 diabetes.

2. Use high-quality androgen testing when appropriate

Start with total and free testosterone, with SHBG or a combined testosterone/SHBG test when useful. Add DHEA-S or androstenedione only when they answer a specific question.

3. Exclude important endocrine mimics

Depending on the presentation, consider pregnancy testing, TSH with Free T4 when indicated, prolactin, and 17-hydroxyprogesterone. Cortisol testing belongs only in a clinician-directed evaluation when features suggest Cushing syndrome.

4. Determine whether ovarian morphology is still needed

If irregular cycles and hyperandrogenism already establish two adult diagnostic features, AMH or ultrasound is generally not needed merely to find a third. If ovarian morphology is still required, use either an appropriate AMH pathway or ultrasound rather than routinely stacking both.

5. Establish glycemic and cardiovascular risk

Assess glycemic status at diagnosis. A 75-g OGTT is the preferred test regardless of BMI. If it cannot be performed, fasting glucose and/or A1C may be considered with lower sensitivity. Obtain a lipid profile at diagnosis and measure blood pressure at least annually.

6. Investigate connected symptoms when indicated

CBC, ferritin, iron studies, thyroid testing, vitamin B12, folate, vitamin D, liver chemistry, kidney markers, or other tests may be useful when a separate symptom or abnormality justifies them. PMOS should not become a reason to order every hormone or nutrient test.

7. Retest what actually changed

Follow the abnormality that originally defined risk: abnormal OGTT or A1C, high triglycerides, elevated liver enzymes, iron deficiency, thyroid dysfunction, or medication-safety markers. Repeating broad testosterone or AMH panels usually adds less value once the diagnostic pattern is established unless symptoms change unexpectedly.

Pattern Recognition: How Connected Results Change the Interpretation

Pattern	What the combination may mean
Irregular cycles + hirsutism + elevated LC-MS/MS testosterone	Provides ovulatory dysfunction plus clinical/biochemical hyperandrogenism. After competing causes are excluded, ovarian morphology may not be required for the adult diagnostic pattern.
Irregular cycles + normal testosterone + elevated DHEA-S	PMOS may remain possible, but adrenal androgen production becomes more relevant. The magnitude of elevation and speed of symptom progression matter.
Apparently regular cycles + hirsutism + biochemical hyperandrogenism	Regular bleeding does not always prove ovulation. Properly timed progesterone may help when confirming ovulation would change management.
Irregular cycles + normal A1C + strong diabetes risk	A normal A1C does not guarantee normal glucose tolerance. A 75-g OGTT may reveal post-challenge dysglycemia.
Rapidly rising or markedly elevated testosterone	Not a routine PMOS pattern. Androgen-secreting ovarian or adrenal disorders and other causes require prompt professional evaluation.
Hair thinning + iron deficiency + normal androgen testing	Iron deficiency may contribute more to hair shedding and fatigue than androgen excess.
PMOS + high triglycerides + abnormal glucose + elevated ALT	Suggests a broader metabolic phenotype involving glucose regulation, cardiovascular risk, and possible metabolic liver disease.
Cycles improving + glucose and triglycerides improving	Multisystem improvement may be more meaningful for follow-up than repeatedly measuring testosterone or AMH.

Important Note About Fasting Insulin and HOMA-IR

Insulin resistance is central to PMOS biology, but Fasting Insulin is not a stand-alone PMOS test, and HOMA-IR does not have a universally accepted cutoff that diagnoses PMOS or determines treatment for an individual patient.

Clinically available insulin assays vary and have limited routine relevance in PMOS care. For guideline-based assessment of glycemic status, the 75-g OGTT, fasting glucose, and A1C have clearer roles. C-Peptide or insulin may be appropriate for selected clinical questions but should not replace validated glycemic testing.

How to Understand PMOS Lab Results

Reference ranges are not diagnostic cutoffs. PMOS guidance does not define one universal “optimal” testosterone, insulin, or AMH range that applies to every patient. Results can vary with age, pregnancy, cycle phase, time of day, fasting status, hydration, recent illness, exercise, medications, supplements, body composition, and assay method.

• Testosterone: confirm that the assay method is appropriate for female concentrations and interpret total/free testosterone with SHBG and symptoms.
• Progesterone: timing matters; a low result can reflect mistimed collection rather than anovulation.
• AMH: age, assay, hormonal contraception, ovarian surgery, cycle timing, and body composition can influence interpretation.
• A1C: anemia, altered red-cell turnover, kidney disease, pregnancy, and hemoglobin variants can affect the value.
• Liver enzymes: abnormal values may warrant evaluation, while normal ALT/AST do not exclude metabolic liver disease.

For more detail on reference intervals, flags, units, and trends, see How to Read and Understand Your Lab Results.

When to Consider PMOS-Related Testing

Testing may be worth discussing with a healthcare professional when someone has persistent irregular cycles, long gaps between periods, hirsutism, acne with menstrual irregularity, scalp hair thinning, infertility, a history of elevated testosterone, acanthosis nigricans, abnormal glucose or lipid results, family history of diabetes, unexplained fatigue, heavy menstrual bleeding, or a prior PMOS/PCOS diagnosis that did not include metabolic assessment.

Testing may also be particularly important when pregnancy is being planned, fertility treatment is being considered, symptoms change rapidly, or a previous result does not fit the overall clinical pattern.

Pregnancy and Fertility Planning Changes the Glucose Strategy

PMOS is associated with additional metabolic risk during pregnancy. Current international guidance recommends considering a 75-g OGTT before pregnancy or when seeking fertility treatment in people with PMOS who do not already have diabetes.

If an OGTT was not completed before conception, it may be offered at the first prenatal visit, and glucose-tolerance testing is recommended again at 24–28 weeks of pregnancy. Blood pressure should also be assessed when planning pregnancy or fertility treatment.

Pregnancy plans can affect medication, contraception, fertility, and monitoring decisions. Laboratory results should therefore be reviewed with an appropriate healthcare professional rather than used independently to start, stop, or change treatment.

How to Prepare for PMOS-Related Blood Testing

• Follow the instructions for the exact test or panel.
• A 75-g OGTT requires fasting and timed collections after a measured glucose drink. Plan enough time to complete the protocol without eating, smoking, or exercising during the test.
• For 17-hydroxyprogesterone, early-morning collection in the follicular phase is generally preferred when feasible.
• Time progesterone to the expected mid-luteal phase—often about seven days before the next anticipated period rather than automatically on calendar day 21.
• Prolactin can rise with sleep, stress, strenuous exercise, eating, and breast stimulation; follow collection instructions and rest before the draw when directed.
• List hormonal contraception, fertility medications, anti-androgens, metformin, GLP-1 medications, steroids, supplements, and recent medication changes.
• Stay normally hydrated unless the test instructions say otherwise.
• Do not stop prescribed medication or hormonal contraception unless instructed by the prescribing clinician.

Questions to Ask Your Healthcare Provider

• Which two diagnostic features do I appear to meet, and which alternative causes still need to be excluded?
• Was my testosterone measured with an appropriately accurate method for female concentrations?
• Should free testosterone and SHBG be interpreted with my total testosterone?
• Could hormonal contraception or another medication be affecting the results?
• Do I actually need AMH or ultrasound, or is the adult diagnostic pattern already sufficient?
• Would a properly timed progesterone test help determine whether I am ovulating?
• Would a 75-g OGTT provide more information than fasting glucose or A1C in my situation?
• How often should glucose, lipids, and blood pressure be reassessed?
• If I go several months without bleeding, what evaluation is appropriate?
• Do any rapidly changing symptoms or markedly abnormal results require imaging or specialist evaluation?

How Ulta Lab Tests Helps

Ulta Lab Tests provides direct online access to many hormone, reproductive, thyroid, glucose, lipid, liver, kidney, blood-count, iron, and nutrient tests where available. Patients can review test information and transparent pricing before ordering, purchase testing without using insurance, use eligible HSA/FSA payment methods where accepted, visit established laboratory networks such as Quest Diagnostics where applicable, and receive results through a secure online account.

Direct access can make it easier to establish a baseline, follow a clinician-directed monitoring plan, or bring objective information to an appointment. It should not be used to delay care for severe symptoms, pregnancy concerns, prolonged amenorrhea, rapid virilization, or markedly abnormal results.

For broader guidance on responsible testing, use these Ulta Lab Tests cornerstone resources:

• The Complete Guide to Lab Tests and Blood Work
• How to Read and Understand Your Lab Results
• Direct-Access Lab Testing: How It Works and What to Expect

Frequently Asked Questions About PMOS Blood Tests

Is PMOS the same condition as PCOS?

Yes. Polyendocrine Metabolic Ovarian Syndrome (PMOS) is the new name adopted in 2026 for Polycystic Ovary Syndrome (PCOS). The name change does not create a new disease. It emphasizes that the syndrome involves multiple endocrine, metabolic, ovarian, reproductive, and lifelong health dimensions and is not defined by abnormal ovarian cysts.

What blood tests are commonly used when evaluating PMOS?

A focused evaluation often starts with total and free testosterone, SHBG, pregnancy testing when relevant, TSH, prolactin, and 17-hydroxyprogesterone. DHEA-S, androstenedione, progesterone, FSH, LH, estradiol, AMH, or other tests may be added for specific questions. Metabolic assessment commonly includes a 75-g OGTT, fasting glucose, A1C, a lipid panel, and a CMP.

Can a blood test diagnose PMOS?

No single blood test diagnoses PMOS. Laboratory results can document biochemical hyperandrogenism, help exclude thyroid, prolactin, pregnancy, or adrenal causes, and measure metabolic risk. Diagnosis requires the full clinical pattern, including menstrual and ovulatory history, androgen-related findings, exclusion of competing causes, and ovarian morphology only when needed.

What is the best testosterone test for PMOS?

Current guidance emphasizes total and free testosterone for biochemical hyperandrogenism. For total testosterone, highly accurate LC-MS/MS methodology is preferred because concentrations in women are relatively low and some direct immunoassays have limited sensitivity and precision. SHBG and medication context can also materially change interpretation.

Does a normal testosterone result rule out PMOS?

No. A person may have clinically meaningful hirsutism or other PMOS features even when testosterone is within the laboratory reference interval. The assay method, SHBG, hormonal contraception, symptoms, and other diagnostic features matter. DHEA-S or androstenedione may sometimes be considered when testosterone does not explain a strong clinical androgen pattern.

Can AMH diagnose PMOS by itself?

No. AMH can be used within the adult diagnostic algorithm as an alternative way to define polycystic ovarian morphology, but it should not be used as a stand-alone PMOS test. If irregular cycles and hyperandrogenism already establish two adult diagnostic features, AMH or ultrasound may be unnecessary simply to find a third criterion.

Why is the 75-g OGTT important in PMOS?

PMOS increases the risk of impaired glucose tolerance and type 2 diabetes regardless of BMI. The 75-g oral glucose tolerance test is the guideline-preferred assessment because fasting glucose or A1C can remain reassuring even when post-challenge glucose handling is abnormal. If an OGTT cannot be performed, fasting glucose and/or A1C may be considered with lower accuracy.

Should fasting insulin or HOMA-IR be used to diagnose PMOS?

No. Insulin resistance is biologically important in PMOS, but clinically available insulin assays have limited routine value and there is no universally accepted fasting-insulin or HOMA-IR cutoff that diagnoses the syndrome. Fasting insulin may be ordered for selected questions, but it should not replace validated glycemic testing such as OGTT, fasting glucose, or A1C.

Is the LH-to-FSH ratio a PMOS diagnostic test?

No. FSH, LH, and estradiol can provide useful ovarian-pituitary context in selected amenorrhea, ovarian insufficiency, hypothalamic, or fertility evaluations, but the LH-to-FSH ratio varies with cycle timing, age, and medications and is not a validated stand-alone test for PMOS.

How often should glucose testing be repeated in PMOS?

Current international guidance recommends reassessing glycemic status approximately every one to three years, based on individual diabetes risk. Earlier testing may be reasonable when previous prediabetes, gestational diabetes, significant weight change, new hyperglycemia symptoms, pregnancy planning, medication changes, or a strong family history increases concern.

Do people with PMOS need metabolic testing if their weight is normal?

Yes. The increased risks of impaired fasting glucose, impaired glucose tolerance, and type 2 diabetes in PMOS occur regardless of BMI. A lipid profile is also recommended at diagnosis regardless of age or BMI, and blood pressure should be measured regularly. Metabolic risk should not be dismissed simply because body weight is normal.

Can I order PMOS-related laboratory tests directly?

Where direct-access testing is available, Ulta Lab Tests offers many of the hormone, glucose, thyroid, lipid, blood-count, iron, and nutrient tests discussed in this article. Direct access can help establish objective information, but results should be reviewed with a qualified healthcare professional who can determine whether additional testing, imaging, or specialist evaluation is needed.

Conclusion: Read the PMOS Pattern, Not One Number

PMOS, formerly PCOS, is best understood as a connected reproductive, endocrine, ovarian, and metabolic pattern. Menstrual history can reveal ovulatory dysfunction; high-quality testosterone testing can document biochemical androgen excess; AMH or ultrasound can clarify ovarian morphology when it is actually needed; and glucose, lipid, blood-pressure, liver, thyroid, blood-count, and iron testing can identify health issues that deserve attention beyond the reproductive diagnosis.

The most useful PMOS blood testing strategy is focused rather than maximal: define the clinical question, use the right test and method, exclude important mimics, assess metabolic risk, and follow the abnormalities that actually matter over time.

Explore relevant testing through Ulta Lab Tests Hormone Testing, Women’s Health Tests, and Diabetes Tests. Review laboratory results with a qualified healthcare professional who can integrate them with symptoms, menstrual history, medications, fertility goals, and any imaging or clinical evaluation that may be needed.

References

1. Teede HJ, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. 2026.
2. American Society for Reproductive Medicine. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polyendocrine Metabolic Ovarian Syndrome.
3. Endocrine Society. Polyendocrine Metabolic Ovarian Syndrome: New name to improve diagnosis and care. May 12, 2026.
4. Monash University. International Evidence-based Guideline for PMOS resources and name-change update.

Summary

PMOS, formerly PCOS, is a multisystem reproductive, endocrine, ovarian, and metabolic syndrome rather than an ovarian-cyst diagnosis. Adults generally meet the diagnostic framework when two of three features—hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology—are present after other causes are excluded.

• Total and free testosterone are the primary biochemical androgen tests; LC-MS/MS is preferred for total testosterone.
• AMH should not be used alone, and AMH or ultrasound may be unnecessary when irregular cycles and hyperandrogenism already establish two adult diagnostic features.
• The 75-g OGTT is the preferred glycemic assessment in PMOS; fasting glucose and A1C are alternatives when OGTT cannot be performed.
• A lipid profile is recommended at diagnosis regardless of age or BMI, and blood pressure should be measured at least annually.
• Fasting insulin, HOMA-IR, and the LH-to-FSH ratio should not be used as stand-alone PMOS diagnostic tests.

Related laboratory tests: total and free testosterone, SHBG, DHEA-S, androstenedione, progesterone, hCG, TSH, Free T4, prolactin, 17-hydroxyprogesterone, AMH when appropriate, 75-g OGTT, fasting glucose, A1C, lipid panel, CMP, CBC, ferritin, iron studies, and selected nutrient tests.

Ulta Lab Tests provides direct access to many relevant laboratory tests where available, helping patients gather objective information to discuss with a healthcare professional. Laboratory testing is informational and should be interpreted with the complete clinical picture.

Medical disclaimer: Laboratory testing provides health information but does not independently diagnose PMOS or replace professional medical advice, physical examination, imaging, treatment, or urgent care. Review abnormal, conflicting, or rapidly changing findings with a qualified healthcare professional